Regarding the commencement of its INSPIRE (International SCENESSE Pilot Repigmentation Evaluation) program to evaluate the use of its first-in-class drug SCENESSE (afamelanotide) as a repigmentation therapy in vitiligo, Dr Mark Lebwohl, Professor and Chair of Dermatology at Mount Sinai Hospital in New York and an investigator on the Clinuvel study, said: I think this is an exciting, major advancement for vitiligo, a disease for which we do not have adequate effective treatments,
Suitable for all skin types, including sensitive skin
Patients need to be committed to these changes for the best results
Tirzepatide is compounded due to the following reasons: Accessibility: Since 2022, Eli Lilly, the manufacturer of Mounjaro and Zepbound, has experienced on-and-off drug shortages due to high demand
All medications come from licensed 503A compounding pharmacies, ensuring consistent quality and safety
The products available on this website are intended solely for in-vitro research purposes (Latin: in glass), meaning they are used in experiments conducted outside a living organism